3 Stocks Crushed by the Market This Week презентация

Plenty of health-care stocks enjoyed big gains this week. But not all of them. Here are three that were hammered pretty hard. 1 2 3

Слайд 13 Stocks Crushed by the Market This Week


Слайд 2Plenty of health-care stocks enjoyed big gains this week. But not

all of them. Here are three that were hammered pretty hard.

1

2

3


Слайд 3Shares of the 3-D bioprinting company dropped nearly 12% this week.


Organovo Holdings (NYSEMKT:ONVO)

Source: Yahoo! Finance


Слайд 4Organovo announced financial results for fiscal 2014 on Thursday
While the results

weren’t great – miniscule revenue and increasing expenses, it’s unlikely that any observer expected any significant positive developments yet on the financial front
The focus for Organovo continues to be future-oriented, especially with the upcoming unveiling of its 3-D liver assay test






Why Organovo’s stock was 3-D: down, down, down


Слайд 5The stock of the biotech fell 11% this week.
Inovio Pharmaceuticals

(NYSEMKT:INO)

Source: Yahoo! Finance


Слайд 6An online post on June 10 speculated that Inovio’s CEO Joseph

Kim was laying the groundwork for announcing negative news about a phase 2 study of cervical dysplasia vaccine VGX-3100
Inovio responded publicly the next day, calling the article “false and misleading” and “inane conjecture”
The company stated that the data from the phase 2 study remains blinded and plans to report results from the phase 2 study by the end of July






Why the market said “no, no” to Inovio


Слайд 7The biopharmaceutical company’s shares dropped 10% for the week.
Orexigen Therapeutics

(NASDAQ:OREX)

Source: Yahoo! Finance


Слайд 8Orexigen announced on Wednesday that the FDA delayed a decision on

weight loss drug NB32 by three months, with a new PDUFA date of Sept. 11
Why the pushback? The FDA indicated that more time is needed to finalize Orexigen’s post-marketing obligations
The main issue relates to evaluation of cardiovascular outcomes
Orexigen has an ongoing study involving 8,900 patients focusing on these cardiovascular outcomes




Why Orexigen’s share price was slimmed down


Слайд 9Organovo’s potential still is intriguing and Inovio could confound critics by

reporting positive results for its DNA vaccine
The nod for best chance of rebounding, though, goes to Orexigen
While the FDA’s delay for a decision on NB32 was disappointing, the prospects for approval likely won’t be impacted
For investors who expect that NB32 will achieve greater success than earlier rivals, this week’s pullback could represent a good buying opportunity

Best shot at bouncing back?


?


Слайд 10Find out which stock The Motley Fool’s chief investment officer selected

as the top pick for 2014 in our free report!

Обратная связь

Если не удалось найти и скачать презентацию, Вы можете заказать его на нашем сайте. Мы постараемся найти нужный Вам материал и отправим по электронной почте. Не стесняйтесь обращаться к нам, если у вас возникли вопросы или пожелания:

Email: Нажмите что бы посмотреть 

Что такое ThePresentation.ru?

Это сайт презентаций, докладов, проектов, шаблонов в формате PowerPoint. Мы помогаем школьникам, студентам, учителям, преподавателям хранить и обмениваться учебными материалами с другими пользователями.


Для правообладателей

Яндекс.Метрика